Pomerantz LLP is investigating claims from investors of Abeona Therapeutics due to potential securities fraud. Concerns arise after recent financial disclosures, impacting stock prices.

Pomerantz LLP is currently investigating potential securities fraud by Abeona Therapeutics Inc. after a recent press release highlighted problematic financial results.

Pomerantz LLP is investigating potential securities fraud on behalf of Abeona Therapeutics' investors following significant stock price drops and questionable claims.

Pomerantz Law Firm has begun an investigation into potential securities fraud involving Abeona Therapeutics Inc. after troubling financial disclosures.

Purcell & Lefkowitz LLP is currently investigating Abeona Therapeutics Inc. over concerns regarding corporate governance and shareholder rights.

Abeona Therapeutics has made a key entry into the dystrophic epidermolysis bullosa (DEB) market by gaining FDA approval for its innovative gene therapy, ZEVASKYN, aimed at treating RDEB.

In a groundbreaking step for the RDEB community, the FDA has approved ZEVASKYN, the first autologous gene therapy for this rare skin disorder. This momentous achievement offers new hope and treatment options.